Comparative Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Advanced Cancer: A Systematic Review and Meta-Analysis
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Comparative Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Advanced Cancer: A Systematic Review and Meta-Analysis
Authors
Keywords
-
Journal
Frontiers in Pharmacology
Volume 11, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2020-02-14
DOI
10.3389/fphar.2020.00040
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial
- (2019) Arnaud Scherpereel et al. LANCET ONCOLOGY
- Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial
- (2019) David Cella et al. LANCET ONCOLOGY
- Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial
- (2019) Maria J Disselhorst et al. Lancet Respiratory Medicine
- Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results
- (2019) Padmanee Sharma et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of combination immunotherapy for malignant solid tumors: A systematic review and meta-analysis
- (2019) Yuhan Wei et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non–small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial
- (2019) Martin Reck et al. EUROPEAN JOURNAL OF CANCER
- Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial
- (2019) Elisa A Rozeman et al. LANCET ONCOLOGY
- Characterization of a novel anti-human lymphocyte activation gene 3 (LAG-3) antibody for cancer immunotherapy
- (2019) Xiaojie Yu et al. mAbs
- Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases
- (2018) E E Vokes et al. ANNALS OF ONCOLOGY
- Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials
- (2018) Sandra P D'Angelo et al. LANCET ONCOLOGY
- Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study
- (2018) Georgina V Long et al. LANCET ONCOLOGY
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- (2018) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
- (2018) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dual PD-1 and CTLA-4 checkpoint blockade promotes antitumor immune responses through CD4+Foxp3- cell-mediated modulation of CD103+ dendritic cells
- (2018) Paul A. Beavis et al. Cancer Immunology Research
- Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
- (2018) Jun Gong et al. Journal for ImmunoTherapy of Cancer
- CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer
- (2018) Yelena Y. Janjigian et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: An open-label, single-arm, multicentre phase II study
- (2018) Kenjiro Namikawa et al. EUROPEAN JOURNAL OF CANCER
- Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
- (2018) Frank Stephen Hodi et al. LANCET ONCOLOGY
- Multicenter Evaluation of the Tolerability of Combined Treatment With PD-1 and CTLA-4 Immune Checkpoint Inhibitors and Palliative Radiation Therapy
- (2017) Andrew Bang et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma
- (2017) Chunyan Hao et al. MEDICINE
- Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143
- (2017) Antonio Omuro et al. NEURO-ONCOLOGY
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2017) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial
- (2016) F Stephen Hodi et al. LANCET ONCOLOGY
- Interdependent IL-7 and IFN-γ signalling in T-cell controls tumour eradication by combined α-CTLA-4+α-PD-1 therapy
- (2016) Lewis Zhichang Shi et al. Nature Communications
- Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer
- (2016) Valsamo Anagnostou et al. Cancer Discovery
- The Journey from Discoveries in Fundamental Immunology to Cancer Immunotherapy
- (2015) Jacques F.A.P. Miller et al. CANCER CELL
- A Threshold Level of Intratumor CD8 + T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1
- (2015) Shin Foong Ngiow et al. CANCER RESEARCH
- Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy
- (2015) Xiangjiao Meng et al. CANCER TREATMENT REVIEWS
- Targeted therapies for treatment of non-small cell lung cancer-Recent advances and future perspectives
- (2015) Joan Minguet et al. INTERNATIONAL JOURNAL OF CANCER
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- (2015) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Monoclonal antibodies against GARP/TGF-β1 complexes inhibit the immunosuppressive activity of human regulatory T cells in vivo
- (2015) Julia Cuende et al. Science Translational Medicine
- Dual Blockade of PD-1 and CTLA-4 Combined with Tumor Vaccine Effectively Restores T-Cell Rejection Function in Tumors
- (2013) J. Duraiswamy et al. CANCER RESEARCH
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma
- (2011) E. J. Lipson et al. CLINICAL CANCER RESEARCH
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
- (2010) M. A. Curran et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Recommendations by Cochrane Review Groups for assessment of the risk of bias in studies
- (2008) Andreas Lundh et al. BMC Medical Research Methodology
- Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways
- (2008) Brian T. Fife et al. IMMUNOLOGICAL REVIEWS
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now